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Combination chemotherapy with gemcitabine and cisplatin in patients with metastatic urothelial cancer of the
bladder frequently results in the development of acquired drug resistance. Availability of cell culture models with
acquired resistance could help to identify candidate treatments for an efficient second-line therapy. Six cisplatin-
and six gemcitabine-resistant cell lines were established. Cell viability assays were performed to evaluate the
sensitivity to 16 different chemotherapeutic substances. The activity of the drug transporter ATP-binding cassette
transporter, subfamily B, member 1 (ABCB1, a critical mediator of multidrug resistance in cancer) was evaluated
using fluorescent ABCB1 substrates. For functional assessment, cells overexpressing ABCB1 were generated by
transduction with a lentiviral vector encoding for ABCB1, while zosuquidar was used for selective inhibition. In this
study, 8 of 12 gemcitabine- or cisplatin-resistant cell lines were cross-resistant to carboplatin, 5 to pemetrexed, 4
to methotrexate, 3 to oxaliplatin, 5-fluorouracil, and paclitaxel, and 2 to cabazitaxel, larotaxel, docetaxel, topotecan,
doxorubicin, and mitomycin c, and 1 of 12 cell lines was cross-resistant to vinflunine and vinblastine. In one cell
line with acquired resistance to gemcitabine (TCC-SUPrGEMCI20), cross-resistance seemed to be mediated by
ABCB1 expression. Our model identified the vinca alkaloids vinblastine and vinflunine, in Europe an already
approved second-line therapeutic for metastatic bladder cancer, as the most effective compounds in urothelial
cancer cells with acquired resistance to gemcitabine or cisplatin. These results demonstrate that this in vitro
model can reproduce clinically relevant results and may be suitable to identify novel substances for the treatment
of metastatic bladder cancer.
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Patients with metastatic urothelial cancer of the bladder are treated
with cisplatin containing systemic chemotherapies (e.g., gemcitabine/
cisplatin, GC) as a standard of care [1,2]. Unfortunately, the
treatment success is limited resulting in a median survival of 12 to 14
months. Treatment failure is commonly caused by development of
resistance to chemotherapy [1,2].
ATP-binding cassette transporter, subfamily B, member 1
(ABCB1) is a cell membrane efflux pump with broad substrate
specificity. Overexpression of ABCB1 in tumor cells develops mostly
as a specific response to ABCB1 substrates (e.g., vinca alkaloids,
taxanes, or anthracyclines) and confers resistance to these substances.
However, ABCB1 may also be upregulated as part of a generalized
stress response to different toxic drugs (such as gemcitabine and
cisplatin), which are not ABCB1 substrates [3,4]. Expression of ABCB1
was detected in both pre-chemotherapy and post-chemotherapy tumor
tissue samples from patients with bladder cancer with higher expression
in post-chemotherapy patients [5–11]. Therefore, efficient second-line
chemotherapies or targeted therapies for the treatment of bladder cancer
need to be tested especially in a context of specific resistance
mechanisms such as ABCB1 overexpression.
Development of acquired cancer cell drug resistance is difficult to
study in a clinical setting. Since acquisition of tumor biopsies
represents an invasive procedure, possibilities to obtain serial tumor
biopsies from patients under chemotherapy are limited by technical as
well as ethical barriers [12]. Moreover, significance of biopsies may be
affected by intratumor heterogeneity [13]. “Liquid biopsies”
including circulating tumor cells and tumor DNA may be valuable
sources for detection of molecular changes associated with resistance
in the future [14] but may be unsuitable for functional studies.
Therefore, experimental in vitro models are needed to identify
potential markers of resistance and novel drug targets.
Drug-adapted cancer cell lines have been successfully used to study
cancer cell mechanisms of resistance [15,16]; however, comprehen-
sive cell line panels are missing. A panel of 18 urothelial cancer cell
lines consisting of six parental chemosensitive cell lines and their
gemcitabine- or cisplatin-resistant sublines was used to study the
activity of 16 anticancer drugs. The cell lines are part of the Resistant
Cancer Cell Line collection. This collection consists of cell lines of 15
different cancer entities including the six gemcitabine- and six
cisplatin-resistant urothelial cancer cell lines that were used here.
Materials and Methods
Drugs
Cisplatin (solvent: 0.9% aqueous NaCl solution) was purchased
from Gry-Pharma (Kirchzarten, Germany), gemcitabine (solvent:
0.9% aqueous NaCl solution) from Lilly (Bad Homburg, Germany),
vinflunine [solvent: phosphate-buffered saline (PBS)] from Pierre
Fabre (Freiburg, Germany), pemetrexed (solvent: DMSO) from Lilly,
methotrexate (solvent: PBS) from Hexal (Holzkirchen, Germany),
carboplatin (solvent: 5% aqueous glucose solution) from Hexal,
oxaliplatin (solvent: PBS) from Teva (Basel, Switzerland), paclitaxel
(solvent: DMSO) from Bristol-Myers Squibb (New York, NY),
topotecan (solvent: dH2O) from GlaxoSmithKline (London, United
Kingdom), docetaxel (solvent: DMSO) from Sanofi (Paris, France),
cabazitaxel (solvent: DMSO) from Sanofi, larotaxel (solvent:
DMSO) from Shanghai Fuhe Chemistry Technology (Shanghai,
China), vinblastine (solvent: PBS) from Teva, doxorubicin(solvent: 0.9% aqueous NaCl solution) from Sigma-Aldrich (St
Louis, MO), mitomycin c (solvent: dH2O) from Medac (Wedel,
Germany), and 5-fluorouracil (solvent: 0.9% aqueous NaCl solution)
from Medac.
Cell Lines and Lentiviral Transduction
The cell lines RT112, RT4, 5637, T24, HT1376, and TCC-SUP
were obtained from the American Type Culture Collection (Manassas,
VA). Drug-resistant sublines were established by continuous exposure
to increasing drug concentrations and are part of the Resistant Cancer
Cell Line (RCCL) collection (http://www.kent.ac.uk/stms/cmp/RCCL/
RCCLabout): RT112rCDDP1000 (cisplatin-resistant, 1000 ng/ml
cisplatin), RT112rGEMCI20 (gemcitabine-resistant, 20 ng/ml
gemcitabine), RT4rCDDP1000, RT4rGEMCI10, 5637rCDDP1000,
5637rGEMCI20, T24rCDDP1000, T24rGEMCI20, T24rVBL20
(vinblastine-resistant, 20 ng/ml vinblastine), HT1376rCDDP1000,
HT1376rGEMCI20, TCC-SUPrCDDP1000, TCC-SUPrGEMCI20,
and TCC-SUPrVBL20.
Cell line adaptation was started with drug concentrations that were
two-fold higher than the respective IC50. The doses were stepwise
increased during subculturing until resistance to clinically achievable
plasma concentration was reached. The establishment of readily
growing resistant cell lines required 1 to 2 years in dependence on the
used cell line and the drug.
The ABCB1-expressing cell lines TCC-SUPABCB1 and T24ABCB1
and the corresponding control cell lines TCC-SUPCER2 and
T24CER2 were established by lentiviral transduction using the
Lentiviral Gene Ontology vector technology as described previously
[17,18].
All cell lines were grown in Iscove’s modified Dulbecco’s medium
(IMDM) supplemented with 10% fetal calf serum (FCS;
Gibco, Karlsruhe, Germany). Cell line authentication was performed
by short tandem repeats (STR) profiling.
Growth Curves
To determine cell growth kinetics, 4000 cells per cm2 were seeded
in cell culture flasks containing IMDM supplemented with 10%
FCS. Cell counts were determined using a Neubauer chamber in the
presence of trypan blue. Doubling time (DT) was calculated using the
formula DT = culture time/cell doubling. Cell doubling = ln(Nf/Ni)/
ln2, where Ni represents seeded cell number and Nf represents the
harvested cell number [19].
Cell Viability Assay
Cell viability was determined by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye reduction assay
after 120-hour incubation as described previously [20]. Drug
resistance was defined by resistance factors defined as IC50
drug-resistant cells/IC50 parental cells. Cell lines were regarded to
be resistant to a drug if the resistance factor was N2 [21].
Flow Cytometry
Antibodies directed against ABCB1 (20 μl per sample with an
antibody concentration of 25 ng/μl; Alexis Biochemicals through
AXXORA Deutschland, Lörrach, Germany) followed by secondary
antibodies labeled with phycoerythrin were used to detect protein
expression by flow cytometry (FACSCalibur; BD Biosciences,
Heidelberg, Germany). Mouse IgG2a antibodies were used as
isotype control.
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1 μM rhodamine 123 (R123, ABCB1 substrate). Zosuquidar (Sigma-
Aldrich), an inhibitor of ABCB1, was added immediately. Cells
were resuspended in supplemented growth medium, and cellular
fluorescence was measured at FL1 channel by flow cytometry.
Statistical Analysis
Results are expressed as mean ± SD of at least three independent
experiments. For statistical analysis, Student's t test, analysis of
variance, and Student-Newman-Keuls test were performed whenever
applicable. Significance was defined at values of P ≤ .05.
Results
Cell Growth Kinetics
Four of six gemcitabine-resistant sublines showed decreased growth
rates compared to their parental cell lines [5637 (DT: 0.96 day)
vs 5637rGEMCI20 (DT: 1.74 day); HT1376 (DT: 1.29 day) vs
HT1376rGEMCI20 (DT: 1.74 day); TCC-SUP (DT: 2.05 day) vs
TCC-SUPrGEMCI20 (DT: 4.91 day); T24 (DT: 0.97 day) vs
T24rGEMCI20 (DT: 1.08 day)], while no significant differences
were found for RT112 cells [RT112 (DT: 1.07 day) vs RT112-
rGEMCI20 (DT: 1.11 day)] and RT4 cells [RT4 (DT: 2.70 day) vs
RT4rGEMCI10 (DT: 2.34 day)]. Three of six cisplatin-resistant
sublines [RT112rCDDP1000 (DT: 0.96 day), RT4rCDDP1000 (DT:
1.65 day), and TCC-SUPrCDDP1000 (DT: 1.30 day)] displayed
enhanced growth rates compared to their parental cell lines, while
growth rate of 5637rCDDP1000 (DT: 1.23 day) cells was decreasedFigure 1. Growth curves of urothelial carcinoma cell lines; 4000 cells p
supplemented with 10% FCS. Cell counts were determined using
displayed as mean ± SD. *P ≤ .05 relative to parental cell line.relative to 5637 cells. For HT1376 vs HT1376rCDDP1000 (DT:
1.30 day) and T24 vs T24rCDDP1000 (DT: 1.03 day), no significant
difference in growth rate was found (Figure 1).Cross-Resistance Profiles
The effects of a panel of 16 anticancer drugs were determined on
the viability of all 18 urothelial cancer cell lines by MTT assay.
Cisplatin-resistant cell lines showed resistance factors to cisplatin
(IC50 resistant cell line/IC50 parental cell line) ranging from 2.78
(HT1376rCDDP1000) to 28.86 (TCC-SUPrCDDP1000).Gemcitabine-
resistant cell lines displayed resistance factors to gemcitabine ranging
from 7.11 (RT4rGEMCI10) to 73.28 (RT112rGEMCI20) relative to
parental cell lines (Suppl. Table 1).
The parental cell line panel included cell lines derived from low-risk
carcinomas (RT4 and 5637) rarely requiring systemic chemotherapy
in vivo [22,23] and those from high-risk carcinomas (HT1376, RT112,
T24, and TCC-SUP) that are commonly treated by chemotherapy
when metastasized. Gemcitabine-resistant sublines of the low-risk
carcinoma cell lines RT4 and 5637 showed resistance to three of the
investigated 16 anticancer drugs (RT4rGEMCI10: gemcitabine,
5-fluorouracil, and carboplatin; 5637rGEMCI20: gemcitabine, meth-
otrexate, and pemetrexed). Cisplatin-resistant sublines were resistant to
three (RT4rCDDP1000: cisplatin, carboplatin, and 5-fluorouracil) and
four (5637rCDDP1000: cisplatin, carboplatin, methotrexate, and
topotecan) of the 16 drugs (Suppl. Table 1).
Gemcitabine-resistant sublines derived from high-risk urothelial
carcinoma RT112, T24, HT1376, and TCC-SUP showed resistanceer cm2 were seeded in cell culture flasks at day 0 containing IMDM
a Neubauer chamber in the presence of trypan blue. Values are
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Cisplatin-resistant sublines of RT112, T24, HT1376, and TCC-SUP
were cross-resistant to up to five agents. In summary, most
pronounced cross-resistance to other chemotherapeutic agents was
observed in gemcitabine-resistant sublines of high-risk urothelial
carcinoma cells (Suppl. Table 1).
Moreover, resistance profiles differed among the investigated
drugs. Eight of 12 investigated resistant cell lines were cross-resistant
to carboplatin, 5 of 12 to pemetrexed, 4 of 12 to methotrexate, 3 of
12 to oxaliplatin, 5-fluorouracil, and paclitaxel, and 2 of 12 to
cabazitaxel, larotaxel, docetaxel, topotecan, doxorubicin, and
mitomycin c. Only one resistant cell line (TCC-SUPrGEMCI20)
was cross-resistant to vinflunine and vinblastine (Figure 2 and
Suppl. Table 1).
ABCB1 Expression in Drug-Resistant Urothelial Carcinoma
Cell Lines
Since ABCB1 overexpression is a major mechanism of resistance to
chemotherapy, we evaluated its role in this model of urothelial
bladder cancer cell lines with acquired drug resistance. TCC-SUP-
rGEMCI20 and T24rGEMCI20 cells showed cross-resistance to
ABCB1 substrates docetaxel, paclitaxel, and doxorubicin (Suppl.
Table 1). The ABCB1 inhibitor zosuquidar sensitized TCC-SUP-
rGEMCI20 cells to vinflunine and vinblastine but not to gemcitabineA
B
Figure 2. (A) The number of gemcitabine-resistant sublines that disp
Cross-resistance was defined as IC50 (as determined by MTT as
Cisplatin-resistant sublines that displayed cross-resistance to additio(Suppl. Table 2). Vinflunine was described to be a weaker ABCB1
substrate than other vinca alkaloids [24]. In accordance, the
relative resistance IC50 TCC-SUP
rGEMCI20/IC50 TCC-SUP and
IC50 T24
rGEMCI20/IC50 T24 was lower for vinflunine than for
vinblastine (Suppl. Tables 1–3).
R123 is a fluorescent dye that is transported by ABCB1. A flow
cytometric assay with R123 was used to determine functional activity
of ABCB1 [25]. Flow cytometry indicated a strong increase of R123
fluorescence after treatment with zosuquidar in TCC-SUP-
rGEMCI20, TCC-SUPrVBL20, TCC-SUPABCB1, T24rGEMCI20,
T24rVBL20, and T24ABCB1 cells compared to cell lines that served as
a control (Figures 3 and 4).
Next, we compared ABCB1 expression and drug sensitivity profiles
in TCC-SUP and T24, TCC-SUPrGEMCI20 and T24rGEMCI20,
TCC-SUPABCB1 and T24ABCB1 (TCC-SUP and T24 cells trans-
duced with a lentiviral vector encoding for ABCB1), TCC-SUPCER2
and T24CER2 (TCC-SUP and T24 cells transduced with a control
vector), and TCC-SUPrVBL20 and T24rVBL20 (TCC-SUP and
T24 cells with acquired resistance to vinblastine, ABCB1 substrate).
Successful transduction of the ABCB1 encoding plasmid in
TCC-SUPABCB1 and T24ABCB1 cells was verified by a significant
increase of ABCB1 expression compared to cells transduced with a
control vector (Figures 3 and 4). Compared to TCC-SUPABCB1,
T24ABCB1, TCC-SUPrVBL20, and T24rVBL20, gemcitabine-layed cross-resistance to additional anticancer drugs is presented.
say) resistant subline/IC50 respective parental cell line N2. (B)
nal anticancer drugs.
A B
Figure 3. (A) R123 fluorescence of TCC-SUP, TCC-SUPCER2, TCC-SUPABCB1, TCC-SUPrGEMCI20, TCC-SUPrCDDP1000, and TCC-SUP-
rVBL20 cells after staining with R123 alone and in combination with 1.25 μM zosuquidar. Values are means ± SD. (B) ABCB1 expression in
TCC-SUP, TCC-SUPCER2, TCC-SUPABCB1, TCC-SUPrGEMCI20, TCC-SUPrCDDP1000, and TCC-SUPrVBL20 cells. IC, isotype control. *P≤ .05
relative to parental cell line.
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expression (Figures 3 and 4). Zosuquidar sensitized ABCB1-expressing
cell lines to ABCB1 substrates with exemption of T24rGEMCI20 cells
(Suppl. Tables 2 and 3).
Discussion
In this study, we established a panel of urothelial cancer cell lines with
acquired resistance to gemcitabine or cisplatin, the standard
therapeutics for patients with metastasized urothelial cancer of the
bladder [1].Rh
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dividing tumor cells might be more vulnerable to chemotherapy.
There was no consistent correlation between cell growth kinetics and
drug sensitivity in the investigated cell lines. This suggests that the cell
growth kinetics are not critical for the drug response in our models.
The most effective compounds among our anticancer drug panel
were vinflunine and vinblastine, since most gemcitabine- or
cisplatin-resistant cell lines were still sensitive to these drugs. Notably,
vinflunine was approved by the European Medicines Agency for
second-line treatment of urothelial bladder cancer on the basis of aT24 
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Vinblastine is a constituent of methotrexate, vinblastine, doxorubicin,
and cisplatin (MVAC), an alternative therapy protocol for metasta-
sized urothelial cancer [27]. This suggests that testing of drug
candidates in drug-resistant cell lines holds potential for identification
of next-line therapies.
Several studies demonstrated ABCB1 overexpression in tumor cells
established from different human carcinomas (e.g., ovarian, stomach,
colon) after adaptation to cisplatin [28–30]. Since cisplatin is not an
ABCB1 substrate, this is probably the consequence of a long-term
non-specific stress response [31,32]. Interestingly, only gemcitabine-
but not cisplatin-resistant cells displayed ABCB1 up-regulation in our
study, being to our knowledge the first report describing gemcitabine-
induced ABCB1 up-regulation in urothelial tumor cells. Thus, ABCB1
expression may affect the efficacy of candidate drugs for second-line
therapies of urothelial cancer after GC failure. In addition, ABCB1may
also modulate the malignant properties of cancer cells (e.g., cell survival,
cell proliferation, and cell invasion) independently of the transporter-
mediated drug efflux [4,33]. Indeed, ABCB1 expression correlated with
an advanced tumor grade or with an increasing risk of recurrence in
urothelial carcinoma patients [7,9]. Therefore, it will be important to
show to which extent GC treatment is associated to an increased
ABCB1 expression.
Cabazitaxel is a taxane that was recently approved for treatment of
castration-resistant prostate cancer [34]. Currently, two clinical trials
that investigate cabazitaxel in advanced bladder cancer are ongoing
(NCT01616875 and NCT01668459). In contrast to taxanes
including paclitaxel and docetaxel that have been used for decades,
cabazitaxel is a weaker ABCB1 substrate [34]. In accordance,
ABCB1-expressing TCC-SUPrGEMCI20 cells remained sensitive
to cabazitaxel. Interestingly, cabazitaxel's resistance profile differed
from those of the other three taxanes in our study. TCC-SUP-
rGEMCI20 and T24rGEMCI20 cells displayed cross-resistance to
docetaxel, paclitaxel, and larotaxel, another taxane under clinical
evaluation [35]. Moreover, HT1376rGEMCI20 cells were cross-
resistant to larotaxel and paclitaxel. In contrast, RT112rGEMCI20
and RT112rCDDP1000 cells showed cross-resistance to cabazitaxel.
Our results show how complex the effects of apparently closely related
compounds can be and that cancer cell line panels are suitable to
identify such differences.
Among platinum derivates, cisplatin and carboplatin are thought to
share a very similar mode of anticancer action [36,37]. In urothelial
carcinoma, cisplatin was found to be superior to carboplatin in a
randomized phase 2 study [38]. The European Association of
Urology recommends carboplatin as a less toxic alternative in patients
that are unfit for cisplatin because of bad performance status or
elevated creatinine levels [39]. In concert with the anticipated closely
related mechanisms of action of cisplatin and carboplatin [36,37], five
of six cisplatin-resistant cell lines were also resistant to carboplatin.
Interestingly, also three of six gemcitabine-resistant sublines displayed
decreased sensitivity to cisplatin (RT112rGEMCI20, TCC-SUP-
rGEMCI20, and T24rGEMCI20), and additionally, three of six
gemcitabine-resistant sublines showed reduced sensitivity to carbo-
platin (RT112 rGEMCI20, TCC-SUPrGEMCI20, and RT4-
rGEMCI10). Therefore, cross-resistance against cisplatin and
carboplatin seems to be common after gemcitabine resistance.
Oxaliplatin supposedly differs in its anticancer mechanism of
action from those exerted by cisplatin and carboplatin [40]. In
concordance with this, oxaliplatin differed clearly in its activity profilefrom the cisplatin and carboplatin efficacy patterns. Only one
gemcitabine- (TCC-SUPrGEMCI20) and two cisplatin-resistant cell
lines (RT112rCDDP1000 and TCC-SUPrCDDP1000) showed
cross-resistance to oxaliplatin. In this context, gemcitabine/oxaliplatin
combination therapy was suggested as an alternative for urothelial
cancer patients unfit for cisplatin [41,42].
Conclusions
Here, we established a novel panel of gemcitabine- and cisplatin-re-
sistant urothelial cancer cell lines. Cross-resistance profiles identified
vinflunine, the European Medicines Agency–approved second-line
therapeutic for urothelial cancer, together with vinblastine as the most
effective drugs. This emphasizes the potential of panels of cancer cell
lines with acquired drug resistance as preclinical models for the
identification of potential next-line therapies after treatment failure.
Notably, ABCB1 expression was detected in two gemcitabine-
resistant cell lines although gemcitabine is not an ABCB1 substrate.
The clinical relevance of these findings needs to be further
investigated. Larger cell line panels may better reflect the complex
processes of resistance formation in urothelial cancer cells [15]. Thus,
the panel of drug-resistant urothelial carcinoma cell lines will be
further expanded and characterized during ongoing research.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2015.04.002.References
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